New research has revealed that a one-year course of a drug called a PARP inhibitor can help to reduce the risk of breast cancer recurrence, and progression to secondary breast cancer, in people with early breast cancer with a change in the BRCA gene.
The targeted therapy Ibrance (chemical name: palbociclib) combined with the hormonal therapy Faslodex (chemical name: fulvestrant) continued to offer better overall survival than Faslodex alone for advanced-stage, hormone-receptor-positive, HER2-negative breast cancer after more than 6 years of follow-up, according to the latest results from the PALOMA-3 trial.
It’s estimated that between 5 to 10 percent of breast cancers result from inherited gene variations. Genetic testing can help detect gene variations that raise your risk of developing breast cancer.
Blog article about breast cancer, lymph nodes and cancer staging.
Blog article written by a breast cancer survivor shares story of family history and BRCA 2 journey.
Blog article about chemotherapy treatment and potential effects on your immune system.
Blog article about HER2-positive breast cancer.
Blog article about BRCA1 and BRCA2 genes and mutations.
Most of those diagnosed with breast cancer wonder if there is some genetic influence. Medical practitioners look at family history of cancer to see if genetic testing is indicated.
